Therapeutic approach
Possibly, because hypertrophic myocardiopathy secondary to tacrolimus is a rare adverse effect, currently there are no guidelines indicating how it should be treated. However, several case reports and observational studies have shown reversal of this side effect with tacrolimus suspension and replacement with another immunosuppressive drug such as Cyclosporine or an mTOR inhibitor 14,17,18,20-22. After switching immunosuppressive therapy to sirolimus, our patient symptoms and echocardiographic findings resolved.